Emirates SkyCargo Becomes First Airline Cargo Carrier To Transport Over 50 Million Doses Of COVID-19 Vaccines

In the run up to World Health Day (7 April), Emirates SkyCargo has become the first airline cargo carrier in the world to have transported more than 50 million doses of COVID-19 vaccines on its flights. The carrier has also transported more than 100 tonnes of syringes across the world to support the delivery of vaccines.

Since the start of international distribution late last year, Emirates SkyCargo has transported over 220 tonnes of COVID-19 vaccines, equivalent to more than 50 million doses, on more than 150 flights from manufacturing locations to 50 destinations on its network through Dubai. Overall, the carrier has transported six different kinds of COVD-19 vaccines.

Nabil Sultan, Emirates Divisional Senior Vice President, Cargo, said: “Emirates SkyCargo is proud to have reached the 50 million COVID-19 vaccine delivery milestone just ahead of World Health Day. As a socially responsible global air cargo carrier, our actions over the last year have always been directed at helping communities across the world, and especially those in developing nations, recover from the devastating impact of the pandemic. We have been leading the global air cargo industry’s efforts and working with our partner organisations in Dubai to rapidly distribute COVID-19 vaccines through Dubai to the rest of the world.”

Emirates SkyCargo has remained agile and dynamic throughout the COVID-19 pandemic, responding quickly to maintain international connectivity for essential goods across the world. The carrier was one of the first in the world to deploy passenger aircraft for cargo only flights in order to transport PPE, medical equipment, pharmaceuticals and food. Over one year, Emirates SkyCargo had operated more than 27,800 flights and transported over 100,000 tonnes of essential commodities.

As early as October 2020, Emirates SkyCargo set up an EU GDP certified dedicated airside hub for distribution of COVID-19 vaccines at its hub in Dubai. With its sophisticated infrastructure and extensive storage capacity, Emirates SkyCargo positioned itself to fly in large quantities of COVID-19 vaccines from manufacturing locations, store the vaccines in Dubai and then regularly replenish vaccine supplies to developing nations with limited cold chain infrastructure through its cargo flights.

In January 2021, Emirates SkyCargo joined hands with leading Dubai-based entities, DP World, International Humanitarian City and Dubai Airports to form the Dubai Vaccine Logistics Alliance to harness the strategic strengths of Dubai as a major global distribution hub for COVID-19 vaccines. In February 2021, Emirates SkyCargo signed an MoU with UNICEF to prioritise transportation of COVID-19 vaccines in support of the COVAX facility which is aimed at equitable global distribution of vaccines.

With its fleet of modern and efficient all wide-body aircraft and a network that currently spans more than 130 destinations across six continents, combined with the strategic geographic location of its state of the art GDP certified Dubai hub, Emirates SkyCargo is a key global player in the secure and rapid global distribution of COVID-19 vaccines.

Clovia Brings Online Shopping Experience Closer To Offline​​ Through Whatsapp And App Based Bra-Bot - The Online Bra Sales Assistant

Clovia, India’s leading brand for women’s innerwear, loungewear, and personal care has recently introduced Bra-Bot - an online AI-based chatbot to help you buy the right innerwear and other categories. This is part of Clovia’s continued effort to bring its online shopping experience closer to assisted offline retail experience and provide its customers technology-driven help for making the right purchase decisions in the product category which boasts of high customer engagement.

Clovia has been one of the key Branded players in the Indian direct-to-consumer space which has been scaling profitably on the back of extensive use of technology in all its business areas. The artificial intelligence-based conversational platform for assisting customers is another step in the same direction. The platform is accessible to customers not only through its site or app, but also through direct engagement via Whatsapp. 

The intent is to bring the customer to as close to an offline retail environment, scalably and in the privacy of their phones. Clovia’s customer engagement on social platforms has been extremely strong through the years. The bra-bot as it’s internally called by the team is capable of understanding the customer’s needs, and point him/her to the correct product while advising on the sizing using Clovia’s proprietary CloviaCurve ™Fit Test. This leads to a frictionless purchase experience while ensuring the customer is not blocked by surges in call traffics or site footfalls.  

The bot can handle a host of issues from helping to make a purchase, to updating you on your orders & delivery status or pointing you to policies, FAQs, or sizing suggestions. The response to the Bra-Bot has been exceptional with almost 2L customers engaging with it within 30 days of launch. The Bot is currently handling over 35% of customer queries automatically and the rest being seamlessly passed to a support executive. “The customers have shown a strong inclination to interact over Whatsapp more than they would like to call - a phenomena which is fast becoming a norm for the millennials. More importantly, the excitement of adoption of the tool from Tier 2/3 Towns is way stronger than the Tier1,” as per Clovia Founder and CEO Pankaj Vermani. The next phase of the bra-bot will see the bot speaking/suggesting differently to individual customers based on their past purchase and browsing patterns leading to a lot more targeted experience at an individual level.

About Clovia:

Clovia is India’s leading direct-to-consumer innerwear and loungewear brand focused on addressing key pain points for millennial women. The company sells 1 unit every 5 seconds on the back of a tech-driven lean supply chain and strong brand positioning. The company over time successfully extended into multiple women's lifestyle categories like activewear, shapewear, maternity, and personal care products. The brand was launched by industry veterans Pankaj Vermani, Neha Kant, and  Suman Chowdhury in 2015. Clovia sells through multiple channels including its exclusive online store www.clovia.com,  Android & iOS Apps, all major online marketplaces, a network of its exclusive retail stores across India, and also through most of the premium large formats in the country. Almost 60% of Clovia business comes through its owned channels, having served over 2Mn customers on the same. At Clovia highly skilled designers and fashion experts create exquisite, playful, and designer products, keeping up with the international designs and styles. Sophisticated, sharp, and suave, contrasted with flirty, fun, and bold prints, Clovia wants to redefine the Indian lingerie market and help customers choose beyond standard cuts, shapes, and colours. The company's proprietary technology stack ensures it has one of the most efficient supply chains in the country. Clovia is backed by Ivy Cap Ventures, Zurich-based Mountain Partners AG, and Singapore-based AT Capital.

Meitra Hospital Collaborates With MGM Healthcare For Their Multi-Organ Transplant Programme

Meitra Hospital has collaborated with Chennai-based MGM Healthcare to set up comprehensive Heart and Lung as well as Liver Transplant Programs. Mr. Faizal E Kottikollon, Chairman, Meitra Hospital and Dr. KR Balakrishnan, Director at Institute of Heart & Lung Transplant& Mechanical Circulatory Support at MGM Healthcare and Dr. Thiagarajan  Srinivasan, Director, Institute of Liver Diseases, Transplant & HPB Surgery, MGM Healthcare signed the Memorandum of Understanding (MoU). Dr. Ali Faizal (Director, Meitra Hospital), and Mr. Harish Manian (CEO, MGM Healthcare) were present at the MoU Signing ceremonies.

Through the Heart and Lung Transplant Program, Meitra Hospital aims to advance its reputed Centre of Excellence for Heart and Vascular Care by offering heart and lung transplants, mechanical circulatory support devices for failing hearts and single lung retrieval and transplant. The transplant programme will be led by an expert team that does the highest number of heart and lung transplants in Asia. 

Dr. K R Balakrishnan has performed more than 375 heart and lung transplants and is credited with performing many first-of-its-kind heart surgeries in India. Dr. Thiagarajan Srinivasan has a personal experience of more than 1,700 liver transplants and a cumulative experience of more than 3,500 liver transplants.

The Liver Transplant Programme, under its Centre of Excellence for Gastro Sciences, will deliver advanced liver transplant services through a multi-disciplinary transplantation team that comprises of dedicated transplant surgeons, gastroenterologists, anaesthetists, intensivists, perfusionists, technicians and nurses.

“This is the next big step in Meitra’sjourney as a quaternary care provider. We are glad to have entered into this partnership with MGM Healthcare for heart, lung & liver transplant surgeries. Dr. K.R Balakrishnan and Dr. Thiagarajan are world renowned transplant surgeons, and it is our privilege to be associated with them for this multi-organ transplantation programme. We are certain that this initiative will help in transforming the healthcare scenario of the region,” said Mr. Faizal E. Kottikollon, Chairman, Meitra Hospital.  

“Our clinical team at MGM Healthcare will be working closely with the clinical team at Meitra Hospital to establish the heart and lung transplant and heart failure management programmes. Medical technology and treatment protocols have greatly evolved over the past few years. Ensuring that patients get the best that medical science has to offer is our primary goal.”, said Dr KR Balakrishnan, Director at Institute of Heart & Lung Transplant & Mechanical Circulatory Support at MGM Healthcare.

Meitra Hospital, a 220-bed quaternary care provider, based in Kozhikode, is already a preferred centre for live and deceased donour renal transplants as well as bone marrow transplants in the region. Through this initiative, it seeks to strengthen its position as a preferred international destination for multi-organ transplants. 

Cure.fit To Sponsor COVID-19 Vaccines For Employees And Trainers

In response to the global pandemic that is still going on, Cure.fit – India’s leading health and fitness platform – will be sponsoring COVID-19 vaccinations for all its employees and trainers.

As soon as the availability of the COVID vaccine is announced, Cure.fit will start deploying them to its entire network. This initiative will be extended to all employees across the country as many are still working from home. Trainers, whose roles are primarily customer-facing, will also be offered vaccines. The company aims to have everyone under this initiative vaccinated in two months.

With the nationwide vaccination drive already underway and many large firms gearing up to facilitate and cover vaccination costs for its employees, this move is especially important for Cure.fit. Given that the company functions in a contact-intensive industry and with offline Cult gyms having opened up across India, this step will help ensure the safety of all its employees against exposure to the COVID-19 virus.

Commenting on this, Sachin Kotangale, Leadership Team, Cure.fit, said: “The health and well-being of our teams is of paramount importance to us, more so because we operate in a contact-heavy customer-facing industry. Our employees have given us a lot in the last year despite facing difficult circumstances. We have tried our best to support everyone since the beginning of the pandemic and will continue to do so. With this decision to provide vaccinations to all our employees, we will continue to offer assistance wherever possible and remain committed to the health and well-being of the entire Cure.fit team.”

About Cure.fit

Cure.fit Healthcare Pvt Ltd is a holistic integrated healthcare platform headquartered in Bangalore. Founded in 2016 by Mukesh Bansal and Ankit Nagori, Cure.fit aims to address preventive healthcare through a combination of engagement, coaching and delivery using a mix of online and offline channels. Cure.fit caters to living a healthy life through its critical dimensions — physical fitness & wellness. Cult.fit, the fitness category, focuses on physical strength through several offline group workout centres & gyms, across top cities in India. Cure.fit is an app-based service provider and is available on Android and iOS.

Lam Research Earns Intel’s 2020 Supplier Continuous Quality Improvement (SCQI) Award

* Lam Research is one of only seven SCQI Award recipients in all of Intel’s global supply chain

Lam Research is proud to announce that it has earned the exclusive Supplier Continuous Quality Improvement (SCQI) Award with distinguished performance in supplier diversity for 2020. This award recognizes the absolute top performers in the Intel supply chain for their dedication to continuous improvement and their performance over the past year.

“Congratulations to Lam Research on receiving Intel’s highest supplier recognition, the SCQI Award. As one of only seven in this elite group in 2020, they truly define world-class performance,” said Dr. Randhir Thakur, chief supply chain officer at Intel. “During a uniquely challenging year, they have earned the Intel SCQI program’s top award through their unwavering commitment to quality, operational excellence, and their close partnership with Intel to accelerate our innovation roadmap.”

The Intel SCQI Award recognizes the highest level of achievement in the Intel SCQI Program, a multiyear road map for continuous improvement for high-performing Intel suppliers. Of the thousands of Intel suppliers around the world, only a few hundred qualify to participate in the SCQI Program.

In 2020, only seven suppliers in the entire Intel supply chain earned an Intel SCQI Award, making them truly the best of the best.

To qualify for an Intel SCQI Award, suppliers must exceed the highest expectations, meet aggressive performance goals and score 95 percent or higher on performance assessments throughout the year. Suppliers must also meet 90 percent or more of their improvement plan and demonstrate outstanding quality and business systems.

About Lam Research

Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. As a trusted, collaborative partner to the world’s leading semiconductor companies, we combine superior systems engineering capability, technology leadership, and unwavering commitment to customer success to accelerate innovation through enhanced device performance. In fact, today, nearly every advanced chip is built with Lam technology. Lam Research (Nasdaq: LRCX) is a FORTUNE 500® company headquartered in Fremont, Calif., with operations around the globe. Learn more at www.lamresearch.com (LRCX-P)

Caution Regarding Forward-Looking Statements

Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to but are not limited to: the performance of the tools we sell or service; the results that our customers can achieve when using our tools; the requirements of our customers for future innovation and the ability of our tools to meet the customers’ future requirements; and the learning that we may obtain from our installed base. These statements are based on current expectations and are subject to risks, uncertainties, and changes in condition, significance, value and effect including those risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission, including specifically the Risk Factors described in our annual report on Form 10-K for the fiscal year ended June 28, 2020 and quarterly report on Form 10-Q for the quarter ended September 27, 2020. These uncertainties and changes could materially affect the forward-looking statements and cause actual results to vary from expectations in a material way. The Company undertakes no obligation to update the information or statements made in this release.

YZF-R15 Version 3.0 Set To Adorn Indian Roads In Metallic Red Colour

 
In continuation with its brand direction, ‘The Call of the Blue’, India Yamaha Motor Pvt. Ltd. today announced another exciting update on the existing range of YZF-R15 Version 3.0. The Super Sports model will now be available in the all new enigmatic ‘Metallic Red’ color from April 1st in India. Adorning the “R series” DNA combined with the elegant Metallic Red look, YZF-R15 Version 3.0 is all set to add a new benchmark with the latest edition that translates the passion of motorcycle racing with excellent performance into stylish appearance creating an everlasting sporty impression. The Metallic Red color edition of YZF-R15 Version 3.0. is priced at Rs. 1,52,100, Ex-showroom Delhi.

Amalgamated with brand’s racing DNA of Exciting, Stylish and Sporty motorcycles, the YZF-R15 Version 3.0 in ‘Metallic Red’ will retain the standard features and specifications of the model which offers a 155 cc, liquid-cooled, 4-stroke, SOHC, 4-valve, fuel-injected engine that uses innovative technologies like Variable Valve Actuation (VVA) and Assist & Slipper (A&S) Clutch. The model is also equipped with a Side Stand Engine Cut-off Switch which prevents engine ignition till the side stand is withdrawn & ensures convenience to riders. All the models in Yamaha Line-up are now available with an in-built Side Stand Engine Cut-off Switch feature.

The BS VI enabled YZF-R15 Version 3.0 is available in 3 existing colours – Racing Blue, Thunder Grey and Darknight. Yamaha will continue to carry forward the rich legacy of the Super Sports Model - YZF-R15 Version 3.0 with such exciting upgradations, thereby enriching the overall experience of the racing enthusiasts in India. 

Creditas Solutions Unveils India’s First Holistic Digital Collections And Recoveries Platform – Ethera

* Ethera is a quantum leap in technology that helps lenders recover loans sans human intervention

Creditas Solutions, India’s leading financial technology company for delinquency management, has announced the launch of Ethera. Ethera is India’s first and only holistic digital debt collections and recoveries platform for banks and financial institutions.

The platform combines predictive and prescriptive analytics, state of the art Machine Learning algorithms and decision intelligence based marketing strategies that resolve problems traditionally faced by banks in the area of delinquency management. It offers a sophisticated customer resolution process for lenders by combining delinquency detection, financial literacy, debt collection and recovery services – all without any human intervention.

Ethera collects data from multiple sources, cleanses it, and further enriches it to understand the borrower’s financial behaviour and segments them basis their credit profiles. It then intelligently creates personalized communication campaigns for each segment by calibrating for optimal content, time, channel, frequency, and preferred language. The result – radically improves engagement rates with customers. Further, all major Indian vernacular languages are supported by the Ethera platform.

For lenders, Ethera holds the promise of new-age technology that cannot only drive up NPA resolution rates but also reduce burdens, such as complex logistics of managing field and customer service agents, manual management of multiple portfolios, and data management.

Speaking at the launch, Anshuman Panwar, Co-founder of Creditas Solutions, Given the inefficiency inherent in traditional manual collections, Creditas has developed Ethera - a fully-integrated platform for automated collections by banks. This is in line with our vision to transform the financial sector in India by deploying new-age solutions that enhance delinquency management capabilities for lenders while at the same time helping borrowers re-enter the credit mainstream in a transparent and humane fashion. The best part is that Ethera has been designed specifically to comply with the banking rules and regulations in the country and is an extremely cost-effective and scalable solution for all financial institutions”

About Creditas Solutions Pvt Ltd

Creditas is India's leading Technology Company in the field of Delinquency Management. Established 6 years ago, Creditas works with Marquee Financial Institutions such as HDFC Bank, SBI Cards, Axis Bank and HSBC to digitally empower their delinquent customer engagement. Its AI-driven solutions have helped lenders improve recovery rates significantly while simultaneously improving the brand experience and customer loyalty.